Skip to main navigation
Go to  Indivior Pharmaceuticals, Inc. corporate website
  • Overview
  • News & Events
    • Results, Reports & Presentations
    • News Releases
    • Events
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Shareholder Info
    • Redomiciliation
    • London Delisting
    • Managing Your Shares
    • Shareholder Meetings
    • Investor FAQs
  • Governance
    • Governance Overview
    • Committees
    • Tax Strategy
  • Financials
    • SEC Filings
    • RNS Filings
  • Resources
    • Contact Us
    • Alerts Service
News & Events
  • Results, Reports & Presentations
  • News Releases
  • Events

News Releases

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
December 10, 2019
Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder
December 2, 2019
New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes
November 11, 2019
Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can “Keep Moving Towards Recovery”
October 31, 2019
Indivior Announces 2019 Third Quarter and Nine Months YTD Results
October 15, 2019
Indivior Raises FY 2019 Net Revenue and Net Income Guidance
September 26, 2019
Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative
July 31, 2019
Indivior Directorate Changes
July 31, 2019
Indivior Announces H1 2019 Financial Results
July 29, 2019
Indivior PLC – Director’s Change of Responsibilities
July 15, 2019
Indivior Announces Ruling by the Court of Appeals for the Federal Circuit in ANDA Litigation
  • Current page 1
  • Page 2
  • Page 3
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 31

Investor Contact

person Jason Thompson
Work Vice President, Investor Relations
drafts InvestorRelations@indivior.com

Subscribe to our Email Alerts

Indivior Pharmaceuticals, Inc. Logo
Indivior Pharmaceuticals, Inc. Logo
© 2026 Indivior Pharmaceuticals, Inc.
This site is intended for US audiences
INDIVIOR is a registered trademark of Indivior UK Limited
Explore
  • Our Company
  • Our Science
  • Our Products
  • Our Impact
Useful Links
  • Terms of Use
  • Privacy Policy
  • Accessibility
  • Cookie Policy
  • Product Query or Adverse Event
Get in touch
  • Contact Us
  • LinkedIn
  • X
  • Our Social Media Community Guidelines
Search Investors